Schmitt M - Search Results

1

Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.

Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M. Harbeck N, et al. Among authors: schmitt m. Clin Cancer Res. 2001 Sep;7(9):2757-64. Clin Cancer Res. 2001. PMID: 11555589

2

Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA).

Chucholowski N, Schmitt M, Goretzki L, Schüren E, Moniwa N, Weidle U, Kramer M, Wagner B, Jänicke F, Graeff H. Chucholowski N, et al. Among authors: schmitt m. Biochem Soc Trans. 1992 Feb;20(1):208-16. doi: 10.1042/bst0200208. Biochem Soc Trans. 1992. PMID: 1321752 Review. No abstract available.

3

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, Klijn JG. Foekens JA, et al. Among authors: schmitt m. Cancer Res. 1992 Nov 1;52(21):6101-5. Cancer Res. 1992. PMID: 1394237

4

Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.

Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Pache L, Graeff H. Schmitt M, et al. Biol Chem Hoppe Seyler. 1992 Jul;373(7):611-22. doi: 10.1515/bchm3.1992.373.2.611. Biol Chem Hoppe Seyler. 1992. PMID: 1515091 Review.

5

Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.

Goretzki L, Schmitt M, Mann K, Calvete J, Chucholowski N, Kramer M, Günzler WA, Jänicke F, Graeff H. Goretzki L, et al. Among authors: schmitt m. FEBS Lett. 1992 Feb 3;297(1-2):112-8. doi: 10.1016/0014-5793(92)80339-i. FEBS Lett. 1992. PMID: 1551416 Free article.

6

Fluorescent probes as tools to assess the receptor for the urokinase-type plasminogen activator on tumor cells.

Schmitt M, Chucholowski N, Busch E, Hellmann D, Wagner B, Goretzki L, Jänicke F, Günzler WA, Graeff H. Schmitt M, et al. Semin Thromb Hemost. 1991 Jul;17(3):291-302. doi: 10.1055/s-2007-1002623. Semin Thromb Hemost. 1991. PMID: 1724574

7

[Flow cytometry DNA analysis of pure cell nuclei from formalin fixed paraffin sections in primary breast cancer: correlation with other prognostic factors].

Harbeck N, Moniwa N, Busch E, Schmitt M, Jänicke F, Fellbaum C, Höfler H, Graeff H. Harbeck N, et al. Among authors: schmitt m. Gynakol Rundsch. 1991;31 Suppl 2:299-302. Gynakol Rundsch. 1991. PMID: 1790958 German. No abstract available.

8

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Jänicke F, Schmitt M, Graeff H. Jänicke F, et al. Among authors: schmitt m. Semin Thromb Hemost. 1991 Jul;17(3):303-12. doi: 10.1055/s-2007-1002624. Semin Thromb Hemost. 1991. PMID: 1796300 No abstract available.

9

Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer.

Schmitt M, Goretzki L, Jänicke F, Calvete J, Eulitz M, Kobayashi H, Chucholowski N, Graeff H. Schmitt M, et al. Biomed Biochim Acta. 1991;50(4-6):731-41. Biomed Biochim Acta. 1991. PMID: 1801751

10

Human tumor cell urokinase-type plasminogen activator (uPA): degradation of the proenzyme form (pro-uPA) by granulocyte elastase prevents subsequent activation by plasmin.

Schmitt M, Kanayama N, Jänicke F, Hafter R, Graeff H. Schmitt M, et al. Adv Exp Med Biol. 1991;297:111-28. doi: 10.1007/978-1-4899-3629-5_10. Adv Exp Med Biol. 1991. PMID: 1837419

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,999 results

Search Page

Filters